🇺🇸

Index Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 07, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent sectors), Q1 2026 showed robust revenue growth averaging 15-25% YoY in 12/20 detailed reporters (e.g., Marcus & Millichap +18.2%, LifeStance +21%, SoFi +42%), but pervasive margin compression (-100 to -200 bps in 6/12 cases like Marine Products -200 bps) and mixed profitability with 7/20 posting losses or declines. Capital allocation remains shareholder-friendly, with $150M+ in buybacks (Marcus $23.5M, First Advantage $33.3M total) and dividends declared (RGA $0.93, BXSL $0.77 Q2). Forward guidance mostly stable or raised (LifeStance revenue to $1.64-1.68B FY, Oportun EPS $1.50-1.65), but commodity/crypto funds (15+ filings) exhibited extreme volatility with AUM surges (Invesco DB Energy +111% QoQ) offset by unrealized losses. Insider patterns limited but positive (Target Hospitality AI/data center expert appointment); M&A advances (Marine Products merger Q2 close). Portfolio implication: Favor growth names with buybacks amid margin pressures; monitor commodity exposure for volatility.

41 high priority 9 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 07, 2026

Q1 2026 filings reveal mixed performance across predominantly financials and select S&P 500 Healthcare biotechs/pharma/devices, with financial institutions driving net income growth averaging 35% YoY (e.g., Citizens +36%, Ponce +45%, Kearny +53%, Chemung +53%, Regions +14%, Velocity +18%) on NII expansion (+17% avg YoY) despite some asset contractions and rising provisions. Healthcare biotechs (MindMed, Generate, NewAmsterdam, Edgewise, Harmony) show widened net losses (avg +50% YoY) from R&D ramps (+30-100% YoY) but robust cash positions ($373-707M, runway to 2028) and clustered Phase 2/3 catalysts in 2Q-Q4 2026. Devices/pharma like BD (new CFO), Zoetis (flat org revenue but raised FY guidance 2-5%, Neogen M&A H2), Harmony (+17% WAKIX revenue) signal resilience amid US softness. Capital allocation favors steady dividends (e.g., Ares $0.15 flat) and buybacks (CoreCivic $55M, CION $9.7M shares). 13F-HRs highlight institutional conviction in healthcare (Lilly, JNJ, AbbVie, Merck) within mega-cap heavy portfolios. Portfolio trends: 70% mixed sentiment, revenue +10% avg YoY but op ex +20% avg, provisioning up in CRE/financials; key implication - watch H2 catalysts for healthcare alpha amid financials' deposit/loan stabilization.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 06, 2026

Across 39 filings in the S&P 500 Technology stream, institutional 13F-HR reports (e.g., Munro, Amica, Palladiem) reveal persistent heavy concentration in core tech names like NVIDIA (top holding in 4/10 13Fs, $288M-$61M positions), Apple, Microsoft, Amazon, and Meta, signaling sustained conviction amid AI/hardware boom. Operational tech firms showed divergent Q1 2026 trends: AMD revenue +38% YoY to $10.3B, EPS +91% to $0.84; Arista +35% to $2.7B, op income +35% to $1.16B; contrasting Ribbon's -10% revenue decline to $163M and widening net loss. Non-tech inclusions highlight cross-sector capital shifts, with positive turnarounds in shipping (Genco +61% rev) but weakness in BDCs (Palmer Square NAV -11% QoQ). Capital allocation mixed: Arista paused buybacks after $787M prior year, while Genco hiked dividend 133% YoY to $0.35/share; forward guidance stable/reaffirmed in Acadia/Immunocore. Portfolio-level: 7/12 10-Qs showed revenue growth averaging +22% YoY, but margin pressures in 4/12 (avg -50bps compression). Key implication: Tech growth intact but watch cash burn/expenses in smaller caps; institutional flows favor AI leaders.

16 high priority 23 medium 39 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 06, 2026

Across 35 filings from NASDAQ-100 related entities, Q1 2026 earnings reveal robust revenue growth in 8/12 operating companies (avg +18% YoY, led by AMD +38% and Kennametal +22%), but mixed profitability with 6/12 showing margin compression or expense pressures (avg op margin flat to -100bps). Institutional 13F-HR filings (13/35) highlight concentrated tech exposure, with NVIDIA topping 5 funds (e.g., Munro $288M, AMICA $61M), signaling sustained conviction in AI/semiconductors. Shipping (Genco) posted a sharp turnaround (+60% revenues, dividend +133% YoY), while biotechs (Immunocore +14% sales, Lyell loss -54%) and autos (Adient +7% sales, profit swing) show recovery glimmers amid cash burn concerns. Capital allocation leans shareholder-friendly with dividends declared in 5 firms (e.g., Genco $0.35, Kennametal $0.20) and buybacks (United Community $37M, Mueller $5.5M). Forward guidance mostly raised/affirmed (Kennametal EPS +18%, Murphy prod beat), building a catalyst-rich H2 2026 calendar. Portfolio implication: Overweight growth industrials/tech, monitor inventory drags and biotech trials for alpha.

14 high priority 21 medium 35 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 06, 2026

Across 50 SEC filings from S&P 500 Financials and related streams dated May 6, 2026, key themes include mixed Q1 2026 earnings with 14/22 reporting companies showing YoY revenue growth averaging +15% (e.g., Clear Secure +19.7%, Amcor +77%), but margin compression in 10/22 averaging -180 bps amid higher costs and investments; robust capital allocation via dividends/buybacks in 9 filings (e.g., Acushnet $10M repurchase, Clear $56.4M returns); and active M&A/debt markets with SPAC IPOs (Quantum Leap $200M, Plutonian $100M) and financings (Bread Financial 4.8M pref shares, Blackstone $450M notes). Financials-specific trends highlight mortgage/REIT consolidation (Two Harbors $11.30/share acquisition at 14% premium) and bank procedural updates (Woori dissent notices, Patriot Q1 prelims). Forward-looking signals positive with 8/15 guidance raises (e.g., BeOne revenue to $6.3-6.5B, LivaNova EPS to $4.20-4.30), building a Q2-Q3 catalyst calendar; 13F-HR filings (14 total) reveal concentrated tech/AI bets (NVIDIA top in 5/14). Portfolio implications: overweight resilient growth names with raised guidance, monitor margin pressures and SPAC de-SPAC risks for alpha.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 06, 2026

Across 50 pre-analyzed SEC filings in the USA S&P 500 Consumer Staples intelligence stream (despite diverse sector representation), Q1 2026 results reveal resilient revenue growth in 70% of reporting companies (avg +9% YoY, ranging from PureCycle +161% to QuidelOrtho -10.5%), tempered by mixed margins (expansions in Elanco +21% Adj EBITDA, Clear Secure +720 bps; compressions in Edgewell -410 bps, Kraft Heinz adj op inc -11.8%). Capital allocation trends emphasize shareholder returns with 15+ companies declaring dividends (e.g., Deluxe $0.30/share, Clear Secure $0.15/share + $56M repurchases) and buybacks (TKO +$1B authorization), alongside debt reductions (Deluxe -$32M, Littelfuse -$166M). Forward-looking statements show 60% guidance raises/reaffirms (Elanco revenue $5.01-5.085B +5-7% org CC, Clear Secure FCF +35.5%), building a catalyst calendar amid M&A momentum (Apellis $41/share + CVR tender, Clear Channel $2.43/share merger by Q3'26). Sentiment skews mixed (55%), with positive outliers in consumer-facing growth (Clover Health rev +62%, members +51%) but bearish pressures from impairments/litigation (Atkore $137M settlement, Fresh Del Monte $20M). Portfolio-level patterns indicate sector stability via promotions (GIS COO elevation) and operational turnarounds (JBT Marel net income +$218M YoY), signaling actionable opportunities in undervalued staples amid modest organic growth (Kraft Heinz -0.4%, Edgewell -2.4%). Overall implications favor defensive positioning with selective growth bets on guidance outperformers.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 06, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including adjacent sectors like energy, pharma, and machinery), sentiment is predominantly mixed (24/50), with 10 positive and 12 neutral/low materiality 13F snapshots; YoY revenue growth averages +20% in 18 key reporters (e.g., AMD +38%, Pattern +43%, ITT +33%), but QoQ declines prevalent in cash/assets (e.g., 8/15 showed -10%+ cash drops) and margins compressed in 7/12 (avg -150bps). Net income surged in outperformers like Parke Bancorp (+52% YoY), SandRidge (+44%), GEO (+96%), but biotechs/pharma (12 filings) reported widened losses from R&D spikes (e.g., Mirum +$775M net loss). Capital allocation bullish: 10 companies hiked dividends/buybacks (e.g., SandRidge +8%, ITT $0.386/share), 5 M&A/deals (e.g., Fresh Del Monte $308M acquisition). Guidance raised in 9/15 (e.g., Pattern +32%, LandBridge $210-230M EBITDA), signaling momentum; portfolio trend: Industrials/energy outperform biotechs on profitability. Implications: Tactical buys in growth industrials (ITT, JCI), caution on cash-burn biotechs; alpha from catalysts like Phase 3 readouts H2 2026.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 06, 2026

Across 17 filings in the USA S&P 500 Energy intelligence stream (with energy-relevant subset including Devon, APA, Chesapeake Utilities, Dorchester Minerals, Hallador Energy, ONEOK), Q1 2026 results show mixed performance: producers like Devon (-14% YoY revenue, -76% net earnings) and Hallador (-13.5% revenue, net loss vs profit) faced headwinds from lower oil/gas/NGL sales and electric volumes, while royalties (Dorchester +36% revenue, +65% net income) and utilities (Chesapeake +18.3% revenue, +16.5% net income) outperformed on volume growth and regulatory tailwinds. APA raised full-year US oil production guidance to 122k bbl/d amid cost savings progress toward $450M, and Hallador secured a 12-year $1B+ capacity deal doubling forward book. Capital allocation trends favor shareholder returns (Dorchester distribution +2% YoY per unit, Chesapeake dividends +7% YoY) and deleveraging (Hallador bank debt to $0, APA repaid $634M bonds). Institutional 13Fs (HughesLittle, Westchester, Copeland) provide neutral snapshots with no major energy shifts. Non-energy filings (Papa Johns mixed AGM votes, Williams Sonoma strong proxy TSR) signal broader market governance focus. Portfolio implication: rotate to resilient midstream/royalties amid E&P volatility, watch Q2 catalysts for guidance updates.

7 high priority 10 medium 17 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 06, 2026

The 50 pre-analyzed SEC filings for USA Dow Jones 30 stream reveal a resilient Q1 2026 earnings season with 18/25 quarterly reporters showing YoY revenue growth averaging +28% (range 4%-108%, led by Viper Energy +108% and Lumentum +90%), though profitability is mixed with 12/25 net income declines averaging -25% due to margin compression (-150bps avg in 8 cases) from rising costs, special charges, and op expenses. Capital allocation remains shareholder-friendly, with 14 companies announcing/declaring dividends (e.g., Acushnet $0.255/share, Flowco +12.5% to $0.09) and 10 executing buybacks totaling ~$300M (e.g., Ingevity $52M, Life Time $62.7M). M&A activity heats up with positive updates on Skyworks-Qorvo (Phase II China review, $500M synergies), Two Harbors-CCM ($11.30/share, Q3 close), and Clear Channel take-private ($2.43/share, vote May 12). Guidance raised in 5 cases (CVS Adjusted EPS $7.30-7.50, LivaNova $4.20-4.30), reaffirmed in 6, signaling cautious optimism; 13F filings show institutional tilt to tech megacaps (NVIDIA, Apple, Amazon topping 8/10 portfolios). Sector patterns highlight energy/materials outperformance vs. manufacturing/construction weakness, with portfolio-level trend of deposit/asset contractions in banks (Parke -2% assets QoQ) but robust cash flows in tech/healthcare. Key implications: Favor growth names with raised guidance and buybacks for near-term upside, monitor M&A catalysts and margin trends for volatility.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 06, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (primarily retail, automotive, restaurants, hotels, entertainment), sentiment is predominantly mixed with 14/25 detailed financial reporters showing YoY revenue growth averaging +12% (e.g., YUM Brands +15%, Marriott RevPAR +4.2%), but margins compressed in 7/15 cases by avg -150 bps amid higher expenses and impairments. Capital allocation remains shareholder-friendly with $1.5B+ in buybacks/dividends (Marriott $0.7B repurchases, SandRidge dividend +8%, Life Time $62M buyback), while M&A activity accelerates (Fresh Del Monte $307M acquisition, Nuveen $347M asset purchase). Forward guidance mixed: 5 raises (Freshpet to 8-11% sales growth) vs 4 cuts (Louisiana-Pacific Siding -2% FY2026). 13F filings reveal institutional conviction in tech-discretionary overlap (Apple/NVIDIA top holdings in multiple). Key theme: Resilience in hospitality/foodservice vs cyclical pressures in building/produce; portfolio implication: overweight restaurants/hotels, underweight commodities-exposed names.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 06, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (primarily pharmaceuticals, biotech, med devices, providers, with some cross-sector), Q1 2026 results reveal mixed performance: 12/18 reporting companies showed YoY revenue growth averaging +18% (led by BeOne Medicines +35%, CoreCivic +25.8%, CVS +6.2%), but 6 experienced declines averaging -15% (e.g., Castle Biosciences -5%, Louisiana-Pacific -21%). Margin trends are divergent with improvements in 7 firms (e.g., Castle gross margin +24pts to 73%, BeOne +4pts to 89%) offset by compressions in 5 (e.g., Edgewell -410bps, Green Thumb -340bps). Guidance was raised by 9 companies (e.g., BeOne FY rev to $6.3-6.5B, CVS Adj EPS $7.30-7.50), signaling optimism amid capex surges and buybacks ($200M+ returned across firms like News Corp $1B program, Chime $200M auth). Capital allocation favors returns (dividends doubled at Atmos, NVE $1.00/shr) over reinvestment, with M&A active (Corebridge-Equitable synergies, CoreCivic $148M acquisition). Biotech catalysts dominate (Revolution Medicines Ph3 success, Sight Sciences $55M patent win), but leadership changes (Anavex CEO exit) and expense inflation pose risks. Portfolio implication: overweight high-growth biopharma with raised guidance, monitor med device margin pressures.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 05, 2026

Across 28 filings in the S&P 500 Technology stream, core tech names like AMD, Arista Networks, CrowdStrike, Klaviyo, and Salesforce showcase explosive revenue growth averaging 28% YoY (AMD +38%, Arista +35%, Klaviyo +28%, CrowdStrike +22%), fueled by AI/data center (AMD DC +57% to $5.8B) and software expansion (CrowdStrike ARR +24% to $5.25B), with institutional 13Fs from Varma, Factory Mutual, and Illinois MRF confirming mega-cap conviction (NVDA/AAPL tops). Guidance trends bullish with raises at AMD (Q2 rev +46% YoY to $11.2B), Arista (Q2 $2.8B), Klaviyo (FY26 $1.51-1.52B +23-24%), offset by mixed margins (Arista GAAP gross -180bps YoY) and cash flow variability. Capital allocation favors buybacks (Salesforce $50B auth, Klaviyo $500M) over dividends in tech, while non-tech filings (banks/REITs) flag provision surges and debt rises. Portfolio-level: Tech outliers outperform with AI catalysts, but watch leadership churn (Klaviyo CFO exit) and QoQ flats. Implications: Overweight AI enablers; sector growth accelerates amid institutional flows.

12 high priority 16 medium 28 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 05, 2026

Across 25 filings from NASDAQ-100 related entities, Q1 2026 results reveal broad revenue growth averaging ~20% YoY in reporting companies (e.g., AMD +38%, Entravision +114%, Weave +17%), but persistent margin compression (PayPal -182bps operating margin, SBA net income -16%) and rising provisions/expenses signal cost pressures amid economic uncertainty. Tech and institutional 13F filings (Varma, Amazon, Sharpepoint, Factory Mutual, Illinois MRF) confirm heavy overweight to NVIDIA, Apple, Alphabet, Microsoft, underscoring sector conviction despite no changes reported. Capital allocation remains shareholder-friendly with buybacks (PayPal $1.5B), dividend increases (Amalgamated +21% to $0.17, Entravision $0.05), and REIT acquisitions (CHCT $28.5M at 9.3% return). Guidance trends positive with raises (Mueller EBITDA to $360-365M, AMD Q2 rev $11.2B +46% YoY) offsetting PayPal's reiterated low-single digit EPS outlook. M&A/partnership activity (Inmune Bio expansion, Richmond merger reminder) and neutral events (auditor changes, bond issuances) add limited alpha, while bio/healthcare shows divergence (INMB positive vs Mustang Bio loss widening). Portfolio implication: Favor semis/ad-tech outperformers; monitor REIT debt rises and bank provisions for downside risks.

11 high priority 14 medium 25 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 05, 2026

Across 50 SEC filings dated May 5, 2026, primarily Q1 2026 earnings and corporate actions, mixed sentiment dominates (65% of filings), with revenue growth averaging +10% YoY in 25 reporters (e.g., Ecovyst +50%, Terex +41%, Paymentus +30%) offset by margin compressions in 15 cases (avg -200bps, e.g., Atkore -780bps) due to costs, impairments, and one-offs. Financials subset (e.g., bank 0000083246 NI +45% YoY, Oaktree BDC income -9% QoQ) shows improving credit provisions (-59% YoY) but deposit/loan pressures. Capital allocation prioritizes returns: $1.8B+ in buybacks/ASRs (Gartner $535M +$600M auth, DuPont $275M, Five9 $90M, Ecovyst $35.7M) and dividends (e.g., Atkore $0.33, Fresh Del Monte $0.30). M&A/divestitures active for focus/delevering (Compass $280M proceeds targeting <1.0x leverage, Helix $107.5M sale, Expro $215M acq). Guidance raised in 8/15 cases (DuPont EPS $2.35-2.40, ADM $4.15-4.70, Ecovyst EBITDA $180-195M), signaling resilience amid macro challenges. SPAC IPOs (CH4 $200M, ARC $105M) highlight M&A appetite. Portfolio implication: Favor capital returners with raised guidance; monitor margin trends and merger closes.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 05, 2026

Across 50 filings from diverse sectors (with Consumer Staples highlights in ADM, Fresh Del Monte, BellRing), results show mixed Q1/FY2026 performance: 65% reported revenue growth averaging +6% YoY (e.g., DuPont +4%, Exelixis +10%, Rockwell +12%), but 55% faced margin compression (avg -200bps, e.g., Atkore -780bps, BellRing gross -530bps) amid input costs, impairments, and one-offs. Capital allocation remains robust with $2B+ in buybacks/dividends (Emerson $2.2B FY, DuPont $275M ASR, KKR $317M), signaling shareholder focus despite $1B+ debt increases in some (Fresh Del Monte +$265M). Guidance raised in 30% (ADM EPS to $4.15-4.70, DuPont sales $7.155-7.215B), lowered in others (QuidelOrtho rev $2.70-2.75B); divestitures unlocked $2.5B+ value (DuPont Aramids $1.2B, Helix $107.5M). Consumer Staples theme: ADM outperforms with +48% Carbohydrate Solutions profit, but Fresh Del Monte -4.9% sales and BellRing volume gains offset by pricing declines signal volume vs. pricing tension. Portfolio trend: Industrials/mats resilient (Emerson margin +320bps), REITs/mortgages pressured (Granite Point net loss improved but portfolio -175M). Implications: Favor guidance-raisers with buybacks for near-term alpha; monitor margin trends and catalysts like Exelixis PDUFA Dec 2026.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 05, 2026

Across 50 SEC filings from S&P 500 Industrials and related sectors for Q1 2026, mixed sentiment prevails in 70% of reports, driven by robust revenue growth in 25 companies (avg +12% YoY, e.g., Eaton +17%, IDEXX +14%) offset by margin pressures (avg -80 bps in 15 firms) and segment declines. Acquisitions dominate capital allocation with $25B+ deployed (Eaton $11B, Waters BD unit), boosting assets but spiking debt (Eaton LT debt +112% to $18.5B). Guidance raised in 12 firms (e.g., Eaton organic 9-11%, Waters rev $6.4-6.45B), signaling conviction amid Aerospace/Electrical strength (+16-21% YoY). Dividend hikes (Sunoco +6.25%, Ferguson $0.89) and buybacks (Dave 7% shares, DuPont $275M ASR) highlight shareholder returns totaling $3B+. Insider patterns limited, but proxy votes (Lattice 95-98% director approval) show alignment; M&A catalysts cluster in Q2-Q3. Portfolio trend: Industrials outpace REITs/pharma with 8/10 revenue beaters, but watch debt leverage (avg 3.5x up 20% YoY in acquirers). Actionable: Favor electrical/aerospace growers, trim high-debt REITs pre-mergers.

9 high priority 41 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 05, 2026

S&P 500 Energy sector filings highlight robust upstream production growth and consolidation via Devon Energy's shareholder-approved merger with Coterra (close ~May 7, 2026, $1B synergies by 2027), alongside mixed Q1 2026 results: EOG Resources led with +27% YoY total production to 1,384 MBoed, +22% revenues to $6.9B, and +30% CFO to $3.0B, while Marathon Petroleum swung to $511M net income (+$585M YoY) on refining margins +$4.36/bbl to $17.74 but midstream EBITDA -7% to $1.6B. Occidental Petroleum showed one-time gains from OxyChem sale boosting net income to $3.2B but continuing ops income -72% YoY to $236M and sales -8% amid debt reduction to $13.3B toward $10B target. Capital returns remain strong with MPC's new $5B buyback, EOG dividends +5% to $1.02/share, and Devon FCF $816M; however, cost pressures (EOG op ex +13%, MPC refining costs +8%) signal margin risks. Neutral 13F filings from Williams Jones and Duncan Williams show no major energy shifts, while non-core filings (CommScope M&A, Real Brokerage merger comms) add minimal sector alpha. Portfolio-level: 4/4 key energy cos reported production beats or guidance tops, but refining/midstream mixed, pointing to upstream outperformance amid consolidation.

5 high priority 8 medium 13 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 05, 2026

Across the 50 pre-analyzed SEC filings from the USA Dow Jones 30 intelligence stream (primarily Q1 FY26 results), mixed sentiment dominates (24/50 filings), with revenue growth averaging +12% YoY in reporting companies (e.g., Entravision +114%, Ecovyst +50%, DigitalOcean +22%) but frequent net income declines or margin pressures (e.g., 8/15 Q1 reporters saw NI drops averaging -40% YoY amid higher opex/capex). Capital allocation remains robust, with 12 companies announcing buybacks/repurchases totaling >$1.5B (e.g., Five9 $90M ASR, Leidos $243M Q1), dividends (e.g., Atkore $0.33/share, Central Ban $0.12/share), and deleveraging via asset sales/M&A (e.g., Compass $280M proceeds, Expro $215M acquisition). Guidance was raised or reaffirmed in 10+ cases (e.g., DigitalOcean to 26% growth, Ecovyst EBITDA to $180-195M), signaling management confidence despite headwinds like input costs, seasonality, and one-offs. M&A and leadership transitions (e.g., Integra new CEO, Devon merger approval closing May 7) highlight portfolio reshaping, while insider buying in Neonode (CEO +80k shares) contrasts dilution risks (AMC 142M new shares). Sector patterns show energy/tech outperformance in topline but profitability volatility, with banks/utilities stable. Implications: Tactical buys in guidance-raisers with buybacks; caution on margin squeezes and liquidity waivers.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 05, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary intelligence stream (primarily retail, automotive, restaurants, hotels, entertainment), Q1 2026 earnings dominate with mixed sentiment: 70% of revenue-reporting companies showed YoY growth averaging +15% (e.g., Shopify +34%, Fabrinet +39%, Life Time Group +11.7%), but 40% faced margin compression averaging -120 bps amid cost pressures (e.g., TransDigm EBITDA margin -140 bps, Fiserv -890 bps). Capital allocation remains shareholder-friendly, with 18 companies announcing/expanding buybacks (total ~$7B incl. TransDigm $905M YTD, DFIN new $150M) and 12 dividend declarations/hikes (e.g., Energy Transfer +3% to $0.3375/unit). M&A/divestitures active in 8 filings (Ferguson 5+ deals, Compass $292.5M sale), supporting deleveraging and growth. Forward guidance largely affirmed/raised (e.g., Energy Transfer EBITDA to $18.2-18.6B, Shopify Q2 high-20s% growth), signaling management conviction despite macro headwinds. Consumer Discretionary outliers shine with resilient demand (First Watch +17% rev, Haverty comp sales +4.3%), positioning for outperformance vs. broader mixed trends. Portfolio implication: overweight growth leaders with strong capital returns; monitor margin trends and Q2 catalysts.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 05, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (though including cross-sector disclosures), dominant themes include mixed financial results in biotechs and medtech with YoY loss narrowing via cost cuts (e.g., Editas -67%, Precision Bio rev +>100x), revenue growth in diagnostics/pharma (IDEXX +14% YoY, Pfizer non-COVID +7%), and leadership transitions (Integra CEO change). Period-over-period trends show 7/12 key healthcare firms with organic revenue growth averaging +6% YoY but margin volatility (e.g., Integra gross +460bps, BrightView net income -73%); financials/funds exhibit NII growth offset by higher provisions (Amalgamated +13.5% NII but prov +>20x). Forward-looking catalysts cluster in H1-H2 2026 (FDA PDUs, trials, AGMs), with capital returns via buybacks (BrightView 1.1M shares, DFIN $28M) signaling confidence amid cash burn. Portfolio-level patterns reveal biotech efficiency gains (R&D cuts 20-34% YoY) contrasting energy funds' revenue declines (avg -30% YoY), implying healthcare resilience vs cyclical weakness. Critical implications: Biotech turnarounds offer alpha; monitor proxy fights (Pacira June 9) and guidance reaffirms (Pfizer FY $59.5-62.5B).

18 high priority 32 medium 50 total filings